BioChromix AB

Our goal is to become a leading diagnostic player within selected neurodegenerative diseases through the development of the unique BCX compounds. BioChromix current focus is in vitro and in vivo diagnostics of Alzheimer’s disease. Alzheimer’s disease affects nearly 1 % of the world population. It is a progressive, degenerative, irreversible disease, and the most common form of dementia. The only reliable diagnosis of Alzheimer’s disease that we have today is post mortem identification of the disease in the brain. The Company's vision is to offer products that enable optimal drug development, patient selection in clinical trials and early disease detection. Main products in development: 1. World class molecular imaging of Alzheimer’s disease (AD) 2. Breakthrough in vitro assays and diagnostics analyzing the oligomeric Amyloid-β (Aβ) biomarker for AD The company protects its technology through an extensive patent portfolio. For more information please visit: www.biochromix.com